Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
SGEN

SGEN - Seattle Genetics Inc Stock Price, Fair Value and News

3711.48USD Delayed

Market Summary

SGEN
USD3711.48
Delayed

SGEN Stock Price

View Fullscreen

SGEN RSI Chart

SGEN Valuation

Market Cap

700.2B

Price/Earnings (Trailing)

-933.34

Price/Sales (Trailing)

304.4

EV/EBITDA

-1.0K

Price/Free Cashflow

-998.58

SGEN Price/Sales (Trailing)

SGEN Profitability

EBT Margin

-32.12%

Return on Equity

-29.42%

Return on Assets

-20.64%

Free Cashflow Yield

-0.1%

SGEN Fundamentals

SGEN Revenue

Revenue (TTM)

2.3B

Rev. Growth (Yr)

27.11%

Rev. Growth (Qtr)

7.42%

SGEN Earnings

Earnings (TTM)

-750.2M

Earnings Growth (Yr)

-13.09%

Earnings Growth (Qtr)

-2.01%

Breaking Down SGEN Revenue

Last 90 days

1522.6%

Trailing 12 Months

1705.6%

How does SGEN drawdown profile look like?

SGEN Financial Health

Current Ratio

2.67

SGEN Investor Care

Shares Dilution (1Y)

1.61%

Diluted EPS (TTM)

-4.01

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20232.1B2.2B2.3B0
20221.7B1.8B1.9B2.0B
20212.3B2.4B1.7B1.6B
2020956.0M1.0B1.9B2.2B
2019709.3M757.6M801.4M916.7M
2018513.7M575.7M609.8M654.7M
2017416.1M428.9M457.9M482.3M
2016365.8M384.1M406.3M418.1M
2015300.6M309.4M317.7M336.8M
2014280.2M275.0M279.8M286.8M
2013219.9M244.6M265.8M269.3M
2012130.9M166.6M195.8M210.8M
201173.2M49.4M54.0M94.8M
201065.8M79.7M93.6M107.5M
200900052.0M

Tracking the Latest Insider Buys and Sells of Seattle Genetics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Dec 14, 2023
romp charles r
back to issuer
-7,739,280
229
-33,796
evp, commercial u.s.
Dec 14, 2023
welch daniel g
back to issuer
-2,456,020
229
-10,725
-
Dec 14, 2023
love ted w
back to issuer
-974,395
229
-4,255
-
Dec 14, 2023
baker bros. advisors lp
back to issuer
-10,661,600
229
-46,557
-
Dec 14, 2023
liu jean i
back to issuer
-11,163,300
229
-48,748
chief legal officer
Dec 14, 2023
simonian nancy a
back to issuer
-14,370,400
229
-62,753
-
Dec 14, 2023
himes vaughn b
back to issuer
-3,406,150
229
-14,874
chief technical officer
Dec 14, 2023
baker bros. advisors lp
back to issuer
-10,238,200,000
229
-44,708,500
-
Dec 14, 2023
simpson todd e
back to issuer
-21,363,900
229
-93,292
chief financial officer
Dec 14, 2023
welch daniel g
back to issuer
-1,087,750
229
-4,750
-

1–10 of 50

Which funds bought or sold SGEN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 15, 2024
FAIRFIELD, BUSH & CO.
sold off
-100
-20,587
-
-%
May 14, 2024
Spotlight Asset Group, Inc.
sold off
-100
-4,243
-
-%
May 01, 2024
Blue Trust, Inc.
sold off
-100
-32,000
-
-%
Apr 30, 2024
Valued Wealth Advisors LLC
sold off
-100
-4,880
-
-%
Feb 21, 2024
Garde Capital, Inc.
sold off
-100
-309,000
-
-%
Feb 16, 2024
HARBOUR INVESTMENTS, INC.
sold off
-100
-41,369
-
-%
Feb 14, 2024
Prospera Financial Services Inc
sold off
-100
-618,703
-
-%
Feb 14, 2024
NinePointTwo Capital LLC
sold off
-100
-260,000
-
-%
Feb 14, 2024
Coppell Advisory Solutions LLC
sold off
-100
-3,855
-
-%
Feb 14, 2024
JET CAPITAL INVESTORS L P
sold off
-100
-6,662,360
-
-%

1–10 of 38

Are Funds Buying or Selling SGEN?

Are funds buying SGEN calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own SGEN
No. of Funds

Unveiling Seattle Genetics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Dec 18, 2023
baker bros. advisors lp
0.0%
0
SC 13D/A
Jun 09, 2023
capital international investors
3.9%
7,227,865
SC 13G/A
May 03, 2023
baker bros. advisors lp
23.8%
44,617,299
SC 13D/A
Mar 13, 2023
baker bros. advisors lp
25.1%
46,985,656
SC 13D/A
Feb 13, 2023
capital international investors
9.7%
18,058,081
SC 13G/A
Feb 09, 2023
vanguard group inc
6.97%
12,945,078
SC 13G/A
Feb 06, 2023
wellington management group llp
5.32%
9,881,292
SC 13G/A
Feb 01, 2023
blackrock inc.
6.4%
11,861,464
SC 13G/A
Mar 10, 2022
baker bros. advisors lp
25.6%
46,975,613
SC 13D/A
Feb 11, 2022
capital international investors
7.0%
12,778,429
SC 13G/A

Peers (Alternatives to Seattle Genetics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
50.9B
6.8B
28.49% 6.05%
-8.53
7.44
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
18.9B
2.0B
2.79% -21.33%
-56.9
9.43
75.20% 68.82%
14.7B
2.5B
-14.30% -15.94%
71.65
5.96
13.74% 186.89%
12.8B
3.8B
8.33% -10.25%
17.2
3.4
8.58% 129.81%
MID-CAP
5.6B
107.9M
20.58% 115.45%
-10.31
48.09
54.84% -28.31%
5.0B
524.1M
-13.99% -52.79%
-12.02
9.57
394.93% 39.61%
3.6B
251.0M
9.96% -0.29%
-12.28
14.5
73.58% -86.73%
3.1B
240.7M
9.94% -31.73%
-6.53
12.77
-1.03% -213.43%
2.4B
813.8M
-14.08% -36.34%
-1.4K
3
56.43% 98.83%
SMALL-CAP
1.9B
411.3M
3.06% 35.16%
29.91
4.73
60.38% -34.49%
1.8B
996.6M
233.93% 75.07%
-4.58
1.83
-26.66% 65.49%
480.9M
881.7K
21.10% 351.81%
-14.25
481.06
-77.61% 33.36%
310.9M
4.9M
8.40% 53.85%
-2.49
63.89
-54.97% 48.23%
17.1M
2.1M
4.76% 108.64%
-0.74
7.61
-13.45% 69.54%

Seattle Genetics Inc News

Latest updates
Yahoo Singapore News07 May 202405:35 am

Seattle Genetics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue7.4%648,650,000603,832,000519,719,000528,150,000510,300,000497,502,000426,460,000429,850,500424,060,000388,478,000331,983,000601,293,0001,061,731,000277,998,000234,514,000289,804,000213,263,000218,447,000195,199,000174,513,000169,424,000
Costs and Expenses6.7%879,988,000824,553,000704,232,000682,154,000703,105,000630,613,000559,510,000601,920,500722,023,000478,081,000454,403,000436,307,000423,545,000371,963,000346,869,000328,218,000303,047,000257,157,000248,836,000264,824,000214,998,000
  S&GA Expenses8.9%265,687,000243,932,000236,441,000216,101,000210,378,000220,259,000174,225,000210,937,000180,281,000165,130,000159,842,000158,365,000127,579,000125,642,000122,249,000115,229,00096,101,00082,331,00080,271,00079,467,00057,155,000
  R&D Expenses12.3%449,047,000399,868,000356,015,000357,843,000384,605,000304,254,000297,659,000304,293,500459,092,000234,861,000230,426,000216,183,500217,670,000198,077,000195,199,000201,061,000196,119,000163,929,000158,265,000149,772,000140,175,000
EBITDA Margin2.3%-0.30-0.31-0.29-0.28-0.32-0.39-0.39-0.40-0.170.270.290.30---------
Income Taxes-120.8%-600,0002,891,0004,600,0004,314,5002,300,000107,0001,300,000-2,334,0001,100,000---1,211,0003,200,000--------
Earnings Before Taxes-3.7%-216,360,000-208,637,000-170,113,000-143,828,000-188,527,000-134,720,000-135,240,000-176,974,000-292,735,000-84,576,000-121,420,000165,884,000639,409,000--25,830,000-91,913,000----
EBT Margin2.3%-0.32-0.33-0.31-0.31-0.34-0.42-0.41-0.43-0.190.250.270.28---------
Net Income-2.0%-215,789,000-211,528,000-174,737,000-148,171,000-190,816,000-134,827,000-136,494,000-174,628,000-293,847,000-84,576,000-121,420,000167,095,000636,167,000-21,190,000-168,402,00025,830,000-91,913,000-79,238,000-13,329,000-119,805,000-67,446,000
Net Income Margin2.8%-0.33-0.34-0.32-0.31-0.34-0.42-0.41-0.43-0.190.250.290.28---------
Free Cashflow64.5%-79,753,000-224,475,000-288,298,000-108,685,000-101,663,000-86,534,000-234,209,000-296,958,000-34,206,000-87,332,000-132,841,000172,634,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets4.0%3,6343,4953,5433,6753,6193,6303,6173,7203,9783,9523,9434,0013,0052,1652,0912,2062,0981,5681,5931,5031,568
  Current Assets1.4%2,5522,5162,6022,8032,7602,7792,7712,8693,1153,0993,1043,0622,1661,3311,1601,1771,196672680654717
    Cash Equivalents38.9%42930833632036837526142568541337455891911724927519364.0084.0078.00115
  Inventory9.1%53148747842736531927620118116314711697.0090.0085.0086.0092.0073.0067.0053.0075.00
  Net PPE16.7%359308264248230219214210209203197197193185175155145131115104101
  Goodwill0%275275275275275275275275275275275275275275275275275275275275251
  Current Liabilities25.1%955763713818726609531569698434390388593283257259246222208225194
Shareholder's Equity-2.6%2,5502,6192,7232,8042,8222,9332,9983,0653,1653,3913,4253,4882,2581,8141,7661,8761,7801,2721,3131,2741,365
  Retained Earnings-8.5%-2,756-2,540-2,329-2,154-2,006-1,815-1,680-1,544-1,369-1,075-990-869-1,036-1,672-1,651-1,483-1,509-1,417-1,337-1,324-1,204
  Additional Paid-In Capital2.8%5,3025,1555,0484,9544,8254,7474,6784,6084,5334,4664,4154,3573,2943,4853,4143,3593,2882,6882,6512,5982,569
Shares Outstanding0.5%189188187187185184184183182181181175---------
Float------24,200---21,000---21,100---7,500---
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations79.6%-35.82-175-249-79.44-85.73-71.77-216-283-17.85-72.44-125189823-86.28-69.06-11.85-60.65-34.01-57.23-24.28-11.12
  Share Based Compensation40.9%13193.0064.0064.0059.0054.0044.0052.0045.0038.0038.0040.0039.0035.0034.0048.0028.0026.0026.0026.0021.00
Cashflow From Investing7.1%142133232-36.4965.0017327.001.0026899.00-78.71-1,323-40.33-76.9322.0065.00-3823.0036.00-16.25-61.56
Cashflow From Financing12.4%16.0014.0030.0065.0018.0015.0027.0022.0022.0013.0020.0077320.0031.0022.0028.0057211.0027.003.0029.00
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

SGEN Income Statement

2023-09-30
Condensed Consolidated Statements of Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues:    
Total revenues$ 648,650$ 510,300$ 1,772,201$ 1,434,262
Costs and expenses:    
Cost of sales165,254108,122457,783301,848
Research and development449,047384,6051,204,930986,518
Selling, general and administrative265,687210,378746,060604,862
Total costs and expenses879,988703,1052,408,7731,893,228
Loss from operations(231,338)(192,805)(636,572)(458,966)
Investment and other income, net14,9784,27841,463479
Loss before income taxes(216,360)(188,527)(595,109)(458,487)
(Benefit) provision for income taxes(571)2,2896,9453,650
Net loss$ (215,789)$ (190,816)$ (602,054)$ (462,137)
Net loss per share - basic (in dollars per share)$ (1.15)$ (1.03)$ (3.21)$ (2.51)
Net loss per share - diluted (in dollars per share)$ (1.15)$ (1.03)$ (3.21)$ (2.51)
Shares used in computation of per share amounts - basic (in shares)188,135184,792187,532184,199
Shares used in computation of per share amounts - diluted (in shares)188,135184,792187,532184,199
Comprehensive loss:    
Net loss$ (215,789)$ (190,816)$ (602,054)$ (462,137)
Other comprehensive income:    
Unrealized gain (loss) on securities available-for-sale, net of tax97(875)1,639(4,472)
Foreign currency translation gain (loss)1893,363(755)6,288
Total other comprehensive income2862,4888841,816
Comprehensive loss(215,503)(188,328)(601,170)(460,321)
Net product sales    
Revenues:    
Total revenues570,729428,0891,583,3431,242,889
Royalty revenues    
Revenues:    
Total revenues63,56143,904144,927111,194
Collaboration and license agreement revenues    
Revenues:    
Total revenues$ 14,360$ 38,307$ 43,931$ 80,179

SGEN Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 428,568$ 319,940
Short-term investments808,4181,415,130
Accounts receivable, net631,555501,912
Inventories531,188427,211
Prepaid expenses and other current assets151,864138,340
Total current assets2,551,5932,802,533
Property and equipment, net358,801248,179
Operating lease right-of-use assets128,86146,738
Intangible assets, net220,255237,516
Goodwill274,671274,671
Other non-current assets100,08064,895
Total assets3,634,2613,674,532
Current liabilities:  
Accounts payable224,813207,851
Accrued liabilities and other729,903610,553
Total current liabilities954,716818,404
Long-term liabilities:  
Operating lease liabilities, long-term113,48743,474
Other long-term liabilities15,6378,835
Total long-term liabilities129,12452,309
Commitments and contingencies
Stockholders’ equity:  
Preferred stock, $0.001 par value, 5,000 shares authorized; none issued00
Common stock, $0.001 par value, 250,000 shares authorized; 188,628 shares issued and outstanding at September 30, 2023 and 186,559 shares issued and outstanding at December 31, 2022189187
Additional paid-in capital5,302,2394,954,469
Accumulated other comprehensive income4,3943,510
Accumulated deficit(2,756,401)(2,154,347)
Total stockholders’ equity2,550,4212,803,819
Total liabilities and stockholders’ equity$ 3,634,261$ 3,674,532
SGEN
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington.
 CEO
 WEBSITEseagen.com
 INDUSTRYBiotechnology
 EMPLOYEES3256

Seattle Genetics Inc Frequently Asked Questions


What is the ticker symbol for Seattle Genetics Inc? What does SGEN stand for in stocks?

SGEN is the stock ticker symbol of Seattle Genetics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Seattle Genetics Inc (SGEN)?

As of Fri Apr 05 2024, market cap of Seattle Genetics Inc is 700.22 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SGEN stock?

You can check SGEN's fair value in chart for subscribers.

What is the fair value of SGEN stock?

You can check SGEN's fair value in chart for subscribers. The fair value of Seattle Genetics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Seattle Genetics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SGEN so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Seattle Genetics Inc a good stock to buy?

The fair value guage provides a quick view whether SGEN is over valued or under valued. Whether Seattle Genetics Inc is cheap or expensive depends on the assumptions which impact Seattle Genetics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SGEN.

What is Seattle Genetics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 05 2024, SGEN's PE ratio (Price to Earnings) is -933.34 and Price to Sales (PS) ratio is 304.4. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SGEN PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Seattle Genetics Inc's stock?

In the past 10 years, Seattle Genetics Inc has provided 0.569 (multiply by 100 for percentage) rate of return.